In Vivo Studies
Mayo Clinic in Florida is internationally recognized for its excellence in developing novel murine models of neurodegenerative disease and has participated in the generation of some of the most widely used transgenic lines, including the Tg2576 model of Alzheimer's disease and the Tg4510 model of frontotemporal dementia.
The laboratory of Malcolm A. Leissring, Ph.D., uses these well-characterized animal models to test novel therapeutic approaches to treating and preventing neurodegenerative diseases. For example, Dr. Leissring's group was the first to show that neuronal overexpression of proteases that degrade the amyloid-beta (Aβ) protein can attenuate or even completely prevent Alzheimer-type pathology in amyloid precursor protein (APP) transgenic mice (see figure).
The discovery that proteolytic degradation of Aβ potently regulates amyloidogenesis has numerous implications for the pathogenesis and prevention of Alzheimer's disease. Dr. Leissring's laboratory is currently pursuing a number of very promising projects derived from this seminal discovery.
© 2013 Mayo Foundation for Medical Education and Research. All rights reserved.